These factors include MM-related issues like amyloidosis, non-MM-related conditions such as older age, diabetes, and obesity, and other aspects linked to MM treatment, such as anthracyclines, corticosteroids, alkylating agents, proteasome inhibitors, and B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor T-cell (CAR-T) therapy [1,2,3,4]. Here, TNFRSF17 is linked to amyloidosis.